European Commission grants marketing authorisation for Incyte's Povofortay (povorcitinib)
Commission Decision (2026) 8206 of 12 November 2026 authorises Povofortay for Incyte Biosciences Distribution B.V., though the Union Register entry does not state the indication.
The European Commission has granted a new marketing authorisation for Povofortay, containing the active substance povorcitinib, according to an entry in the Union Register of medicinal products for human use. The decision is Commission Decision (2026) 8206, dated 12 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.